In a recent Phase I trial, IL-15-armored GPC3-CAR-T cells outperformed conventional CAR-T cells by resisting the immunosuppressive TME, expanding more robustly, persisting longer, and accumulating in a functional, metabolically fit state, leading to tumor regressions and disease control in a subset of patients [117]. The gene discussed is IL15; the disease is neoplasm.